Dr. Peter Grandsard is currently the Executive Director of Amgen’s Center for Research Acceleration by Digital Innovation (CRADI). This R&D center strives to advance the discovery, design, and development of breakthrough differentiating therapeutics as well as our understanding of disease biology through industry-leading experimentation and digital innovation. To that end, it generates, manages, and analyzes data at scale, and provides actionable insights from computational biology, physical and statistical modeling (AI/ML).
Since joining Amgen in 1996, he has had a variety of roles and responsibilities. Trained as a chemical engineer (BE/ME) and as an analytical chemist (Ph.D.), he started as a scientist designing and implementing new laboratory automation and instrumentation. Later he led that team of engineers, physicists, biologists, and chemists, to increase therapeutics discovery and development efficiency, or to enable new activities. In 2011, Peter started leading another diverse organization (DAS, Discovery Attribute Sciences) with a remit to analyze therapeutic candidates and reagents, biologics or synthetics alike, in order to understand their structures, their physical-chemical attributes, and their protein target binding properties. Since early 2022, Peter has been leading CRADI focused on increasing the utility of physical and statistical modeling in Amgen R&D.